BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples